For research use only
| Cat No. | ABC-TC0441 |
| Product Type | Human Colon Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | HUTU80, HUTU 80, hutu-80 |
The cells express receptors for bombesin at up to 6000 sites per cell.
HuTu-80 is a human duodenal adenocarcinoma cell line established from in situ small intestine tumor tissue of a 53-year-old male patient with adenocarcinoma of the duodenum. It exhibits an epithelial-like morphology and grows as adherent monolayers under standard culture conditions. Cytogenetic profiling indicates a pseudodiploid karyotype with a modal chromosome number of 46, while detailed mutation analyses have revealed a heterozygous CTNNB1 p.Ser37Phe mutation relevant to Wnt/β-catenin signaling alterations in tumor biology. HuTu-80 cells have a doubling time of approximately 26–30 hours and are microsatellite stable (MSS), supporting their use in pharmacogenomic and pathway studies. These cells are tumorigenic in immunodeficient models and have been used to investigate mechanisms such as metabolic regulation and signal transduction in small bowel carcinoma contexts. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HUTU80, HUTU 80, hutu-80 |
| Species | Human |
| Cat.No | ABC-TC0441 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Colon Cancer Cell Lines |
HuTu-80 cell line is used as an in vitro model of human duodenal adenocarcinoma for studying tumor cell proliferation, signal transduction pathways, and responses to therapeutic agents, including analyses of metabolic reprogramming and drug sensitivity relevant to small intestine cancers. This line is also applied in research exploring the mechanisms of Wnt/β-catenin signaling and targeted drug effects in gastrointestinal oncology.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
